SenesTech Earnings Call Transcripts
Fiscal Year 2026
-
A new CEO with deep consumer products experience is leading a strategic shift to prioritize direct-to-consumer growth, recurring revenue, and brand awareness, while revamping B2B approaches for targeted verticals. Operational improvements and a focus on profitability and accountability are expected to drive measurable progress.
-
Q1 2026 saw record growth in direct-to-consumer, subscription, and B2B revenues, with gross margin reaching 68.6%. Strategic shifts to in-house Amazon management and a focus on recurring revenue are driving momentum, and management expects continued quarter-over-quarter growth.
Fiscal Year 2025
-
Revenue grew 20% to $2.2M in 2025, with e-commerce up 88% and gross margin rising to 62.5%. Adjusted net loss improved, and the company resolved major litigation, expanded internationally, and is targeting accelerated growth in 2026.
-
Record Q3 revenue was driven by strong e-commerce, retail, and municipal growth, with gross margins at 63% and adjusted EBITDA loss at a historic low. The company maintains a solid cash position and expects continued expansion, including international markets and new retail partnerships.
-
Rodent birth control solutions are disrupting a $4.5 billion global market, driven by regulatory bans on poisons and demand for humane alternatives. Evolve, the new top-selling product, has fueled 56% revenue growth and margin expansion, with strong e-commerce and municipal traction. International and government channels are set to accelerate future growth.
-
A science-driven rodent control company is rapidly expanding with its Evolve soft bait, leveraging regulatory tailwinds, a strong competitive moat, and multi-channel distribution. Revenue and margins are growing, with a robust cash position and clear path to profitability.
-
Record Q2 revenue and gross margins were driven by Evolve's rapid adoption, with e-commerce and municipal sales surging. The company is well-funded, expects continued growth across all channels, and targets cash flow break-even in late 2026.
-
A novel fertility control approach is driving rapid growth in rodent management, with Evolve sales up 40% and gross margins doubling. Expansion in e-commerce, municipal, and international channels, along with cost optimizations, positions the business for profitability and industry transformation.
-
Q1 2025 revenue rose 17% year-over-year, driven by 40% growth in the high-margin Evolve product line and a 107% surge in e-commerce sales. Gross margin reached a record 64.5%, and municipal and international deployments are expected to fuel further growth.
-
Rapid adoption of new solid-form rodent control products has driven significant revenue and margin growth, with Evolve now comprising 70% of sales. Municipal and international deployments are expanding, and financial efficiency improvements position the company for potential profitability by 2026.
Fiscal Year 2024
-
Record Q4 and FY2024 results driven by Evolve, with revenue up 70% and gross margin at 61%. Cost reductions and strategic financing position the company for near-term cash flow break-even, while expansion in e-commerce, municipal, and international markets fuels growth.
-
Record Q3 revenue and gross margin were driven by rapid adoption of Evolve Rat and Evolve Mouse, with significant growth in e-commerce and international orders. Operating expenses fell, cash burn was reduced, and the company is on track for cash flow break-even next year.
-
Fertility-based rodent control solutions are driving rapid revenue growth, with Evolve and a new mouse product expanding market reach. Distribution is broadening internationally and across major U.S. retail and e-commerce channels, with financials improving and cashflow breakeven targeted for early 2025.
-
Record sales growth of 62% year-to-date was driven by the Evolve product line, with gross margin reaching 67% in June. Expansion into new markets and channels, plus large potential retail orders, position the company for possible profitability next year.